In addition, constitutive activation of the PI-3K/AKT/mTOR pathway has been observed in hematological malignancies including ALL [9], making the PI-3K/mTOR pathway a potential therapeutic target for the treatment of this disease. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.